P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

123 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however there are no current WHO treatment guidelines for this infection. There are both health cost benefits to a more rapidly acting agent, and due to difficulties with microscopic identification there may be more effective treatment for all malaria species if an aligned treatment guideline could be supported. We are currently conducting a separate RCT using a similar protocol evaluating artesunate-mefloquine versus chloroquine for uncomplicated P. knowlesi malaria. However artemether-lumefantrine should also be compared against chloroquine due to the fact it is also a first line anti-malarial recommended in Malaysia, and there are potential differences in efficacy due to the different administration, absorption and half-life of artemether-lumefantrine.

The investigators aim to test whether the fixed combination of artesunate-mefloquine is superior to chloroquine in order to define the optimal treatment for both uncomplicated P. knowlesi infection in both adults and children in this region.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine

NCT01708876

Uncomplicated Plasmodium Knowlesi Malaria

COMPLETED PHASE3

Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia

NCT02348788

Plasmodium Vivax Malaria Without Complication

UNKNOWN PHASE3

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

NCT02741024

Malaria

COMPLETED PHASE4

Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria

NCT00529867

Malaria, Falciparum

COMPLETED PHASE4

TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

NCT04222088

Malaria Falciparum Malaria Vivax Malaria +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Naturally acquired infections with Plasmodium knowlesi, the fifth human malaria, are growing \[1\]. Since 2004 increasing numbers of cases have been reported from residents and returned travelers predominantly from Malaysia and other countries in South-East Asia including Thailand, Vietnam, Myanmar, Singapore, Indonesia and the Philippines \[2-8\]. Cases coincide with the geographic distribution of its natural simian hosts (long-tailed and pig-tailed macaques) and Anopheles leucosphyrus group mosquito vector \[9, 10\], with potential human-to-human transmission unknown. Eastern Malaysia appears to be the epicentre, with around 1400 PCR-confirmed P. knowlesi human mono-infections reported in 2009, comprising 41% of 2,189 total malaria cases in Sarawak \[11\] and 343 cases from selected samples sent to Sabah's State Reference Laboratory \[12\]. P. knowlesi is also now the most common cause of malaria in different contrasting regions, including 70% of malaria admissions in the heavily forested area of Kapit in Sarawak \[1, 13\], 63% of samples from the interior division of Sabah \[14\], and in 87% of malaria admissions in the deforested coastal area of Kudat in Sabah, where it is also the major cause of malaria in children \[15\].

Despite the increase in reported incidence, difficulties with microscopic diagnosis and a lack of PCR based epidemiological surveillance studies throughout South-East Asia mean the true disease burden is underestimated. P. knowlesi is microscopically misidentified as P . falciparum and P. malariae due to morphological similarities in the early trophozoite, and late trophozoite and schizont life stages respectively, with studies showing up to 80% of P. malariae \[16-19\] and 7-12% of P. falciparum \[1, 16\] in this region are actually P. knowlesi when definitively evaluated with PCR. Misdiagnosis has concerning treatment implications, as unlike P. malariae, knowlesi malaria has a rapid 24-hour replication rate and can cause hyperparasitaemia, severe complications and fatal outcomes \[13, 17, 18\], while the inadvertent use of chloroquine for widely chloroquine-resistant P. falciparum may also have fatal consequences.

Naturally acquired infections with Plasmodium knowlesi, the fifth human malaria, are growing \[1\]. Since 2004 increasing numbers of cases have been reported from residents and returned travelers predominantly from Malaysia and other countries in South-East Asia including Thailand, Vietnam, Myanmar, Singapore, Indonesia and the Philippines \[2-8\]. Cases coincide with the geographic distribution of its natural simian hosts (long-tailed and pig-tailed macaques) and Anopheles leucosphyrus group mosquito vector \[9, 10\], with potential human-to-human transmission unknown. Eastern Malaysia appears to be the epicentre, with around 1400 PCR-confirmed P. knowlesi human mono-infections reported in 2009, comprising 41% of 2,189 total malaria cases in Sarawak \[11\] and 343 cases from selected samples sent to Sabah's State Reference Laboratory \[12\]. P. knowlesi is also now the most common cause of malaria in different contrasting regions, including 70% of malaria admissions in the heavily forested area of Kapit in Sarawak \[1, 13\], 63% of samples from the interior division of Sabah \[14\], and in 87% of malaria admissions in the deforested coastal area of Kudat in Sabah, where it is also the major cause of malaria in children \[15\].

Despite the increase in reported incidence, difficulties with microscopic diagnosis and a lack of PCR based epidemiological surveillance studies throughout South-East Asia mean the true disease burden is underestimated. P. knowlesi is microscopically misidentified as P . falciparum and P. malariae due to morphological similarities in the early trophozoite, and late trophozoite and schizont life stages respectively, with studies showing up to 80% of P. malariae \[16-19\] and 7-12% of P. falciparum \[1, 16\] in this region are actually P. knowlesi when definitively evaluated with PCR. Current rapid diagnostic tests (RDT) for malaria can distinguish falciparum Current rapid diagnostic tests (RDT) for malaria can distinguish falciparum from other Plasmodium species with a sensitivity of up to 99% at parasite counts \> 1,000/ μL \[20\], but a knowlesi specific antigen has not been developed and current antibody panels are unable to differentiate between P. knowlesi and other mixed Plasmodium spp. infections \[21\]. Misdiagnosis has concerning treatment implications, as unlike P. malariae, knowlesi malaria has a rapid 24-hour replication rate and can cause hyperparasitaemia, severe complications and fatal outcomes \[13, 17, 18\], while the inadvertent use of chloroquine for widely chloroquine-resistant P. falciparum may also have fatal consequences.

Artemether-lumefantrine (A-L) is a common and widely available ACT, and along with artesunate-mefloquine (AS-MQ) is one of only 2 first line WHO recommended options for the treatment of uncomplicated P.falciparum infection which are registered in Malaysia and produced according to international good manufacturing practice (GMP) standards. ACTs are the current mainstay of malaria eradication efforts 28, with a mechanism of action resulting both in a rapid reduction in parasite mass and resolution of clinical features, while the long acting component eliminates residual parasites and delays the development of de novo resistance 29,30.

Initial reported use of A-L for knowlesi malaria was from our retrospective study at a tertiary referral hospital in Sabah, where a small sample size of 8 out of 34 patients with PCR confirmed uncomplicated P.knowlesi infection were treated with oral artemether-lumefantrine. Median microscopic parasite clearance time was 1 day (range 0-3), which was significantly faster than those receiving chloroquine (median 2.5 days, range 1-3), while this also resulted in fewer days of hospitalization and health sector associated costs. The proportion remaining parasitaemic at day 1 was 33% 16. Our subsequent prospective study at the same site documented 109 knowlesi malaria patients successfully treated with A-L, with no recurrences identified. Unpublished data from this study showed that of the patients with uncomplicated P. knowlesi malaria enrolled, 51 received A-L monotherapy, with a median parasite clearance time of 2 days31.

Evaluation of A-L is required in addition to AS-MQ, as there are a number of pharmacokinetic and pharmacodynamic differences that may affect clinical outcomes. In contrast to AS-MQ, adequate oral absorption of A-L requires co-adminstration with fatty foods, with twice daily dosing28. The longer acting partner drug in A-L is lumefantrine, which has a half life of 3 days compared to mefloquine in AS-MQ which is 21 days. Therefore there may be differences in P. knowlesi recurrence at day 28 or 42 as the follow up time recommended by WHO for anti-malarial efficacy monitoring studies 32.

Chloroquine with primaquine was initially suggested to have favourable treatment outcomes for uncomplicated P. knowlesi human infections after a retrospective review of patients from Kapit Hospital in Sarawak in 2004 15. Following this a single prospective observational study conducted at the same site between 2006-7 administered chloroquine as a total base dose of 25mg/kg and primaquine as a gametocidal agent to 73 patients with uncomplicated PCR-confirmed P. knowlesi malaria, with results showing median fever clearance of 26 hours, mean times to 50% and 90% microscopic parasite clearance of 3.1 and 10.3 hours respectively, and a median PCR adjusted clearance time of 3 days. The proportion remaining parasitaemic at day 1 was 55%. None of the 60 patients who completed the 28-day follow up demonstrated any evidence of resistance, re-infection or recrudescence 25.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uncomplicated Knowlesi Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Artemether-lumefantrine

Artemether-lumefantrine.

1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; \>35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, \>10-15kg = 1 tablet.

Group Type ACTIVE_COMPARATOR

Artemether-lumefantrine combination

Intervention Type DRUG

Chloroquine

Chloroquine.

1 tablet contains 155mg chloroquine base. Adult dose (\>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.

Child dose (\>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours.

Group Type ACTIVE_COMPARATOR

Chloroquine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artemether-lumefantrine combination

Intervention Type DRUG

Chloroquine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Riamet Co-Artem Chloroquine; 1 tablet = 155mg base

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients at least 1 year of age and weighing more than 10kg.
* Microscopic diagnosis P. knowlesi (including diagnosis as P. malariae) or P. falciparum infection (any parasitaemia).
* Negative P. falciparum malaria rapid diagnostic test (histidine rich protein 2)
* Fever (temperature ≥37.5°C) or history of fever in the last 48 hours.
* Able to participate in the trial and comply with the clinical trial protocol.
* Written informed consent to participate in trial; thumbprint is required for illiterate patients, and written consent from parents/guardian for children below age of consent.

Exclusion Criteria

* Clinical or laboratory criteria for severe malaria, including warning signs, requiring parenteral treatment according to modified WHO criteria (see Appendix 4)
* Parasitaemia \> 20,000 /μL
* Inability to tolerate oral treatment
* Concomitant infection with any other malaria species
* Positive for P. falciparum histidine-rich-protein-2 by malaria rapid diagnostic test
* Pregnancy or lactation
* Unable or unwilling to use contraception during study period
* Known hypersensitivity or allergy to artemisinin derivatives
* Serious underlying disease (cardiac, renal or hepatic)
* Received anti-malarials in previous 2 months
* Previous psychiatric illness or epilepsy
* Previous episode of cerebral malaria

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jayaram Menon, MBBS

Role: STUDY_DIRECTOR

Sabah Ministry of Health